In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
This activity has been designed to meet the educational needs of the interprofessional team, including medical oncologists, thoracic surgeons, and all members of the healthcare team involved in the management of patients with small cell lung cancer.
After participating in this educational activity, participants should be better able to:
- Apply the latest evidence and guidelines to individualize second-line treatment plans for patients with extensive-stage small-cell lung cancer
- Implement evidence-based strategies to prevent, monitor, and manage adverse effects in patients receiving second-line treatment for extensive-stage small-cell lung cancer
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Ticiana Leal, MD, faculty for this educational event, is a contracted researcher for Pfizer, Bayer, and Advaxis; receives consulting fees from Amgen, AstraZeneca, Janssen, Takeda, EMD Serono, Daiichi-Sankyo, Eisai, Novocure, Roche/Genentech, Regeneron, Merck, Jazz, Catalyst, Pfizer, and Novartis.
Jacob Sands, MD, faculty for this educational event, is a contracted researcher for AstraZeneca, Lilly, Merck, Daiichi-Sankyo, Regeneron, BioAtla, Agenus, BMS, Duality, Prelude, Blueprint, Dizal Pharma, Bayer, Redcloud, Mirati, and Verastem; and receives consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, G1 Therapeutics, Pfizer, Pharma Mar, and Takeda.
The following planners/reviewers/managers have disclosed:
Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.
William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.
Total CME, LLC., planners and managers have no relevant commercial relationships to disclose.
All the relevant financial relationships for these individuals have been mitigated.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.
This activity is supported by an independent educational grant from Jazz Pharmaceuticals, Inc.
During the period 11/30/2023 through 11/30/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.